REMARKS

Applicants have amended claim 1 of U.S. Patent No. 5,902,821, and have added new claims 12-30. In accordance with 37 C.F.R. § 1.173(c), Applicants have provided herein a table of exemplary support for the claim amendments and the new claims. Claims 1-30 are pending in the application.

TABLE OF EXEMPLARY SUPPORT

Claim	Exemplary Support for Claim Amendments/New Claims
1	*See, e.g.,* col. 7, ln. 56-59 ("The maintenance phase of each study ranged from six to 12 months, after which patients had the option of receiving open-label carvedilol in an extension study."); col. 1, ln. 9-14 ("The present invention relates to a new method of treatment ... for decreasing the mortality of patients suffering from congestive heart failure ...."); col. 3, ln. 59-63 ("carvedilol [is] able to decrease the mortality resulting from CHF in humans by about 67 percent."); col. 6, ln. 61-62 ("This represented a reduction in risk of death by [carvedilol] of 67% ....").
12	*See, e.g.,* col. 1, ln. 9-14 ("The present invention relates to a new method of treatment ... for decreasing the mortality of patients suffering from congestive heart failure ...."); col. 3, ln. 59-63 ("carvedilol [is] able to decrease the mortality resulting from CHF in humans by about 67 percent."); col. 6, ln. 61-62 ("This represented a reduction in risk of death by [carvedilol] of 67% ....").
13	*See, e.g.,* col. 6, ln. 49-53 ("After a common screening period, patients with class II-IV CHF ... and an ejection fraction of <0.35 were assigned to one of four protocols ...."), col. 6, ln. 62-64 ("The treatment was similar in patient with class II and class III-IV symptoms.")
14	*See* exemplary support for claim 1, above.
15	*See* exemplary support for claim 12, above.
16	*See* exemplary support for claim 13, above.
17	*See* exemplary support for claim 1, above.
18	*See* exemplary support for claim 12, above.
19	*See* exemplary support for claim 13, above.
20	*See, e.g.,* col. 5, ln. 19 – col. 6, ln. 15; claim 7.
21	*See, e.g.,* col. 5, ln. 54-60 ("In the event the patient exhibits medically acceptable tolerance of the compound [at the starting dose] for two weeks, the dosage is doubled at the end of the two weeks and the patient is

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

	maintained at the new, higher dosage for an additional period, preferably to two more weeks.... This course is continued until the patient is brought to a maintenance dose."); col. 6, ln. 1-12 ("The present invention also relates to a method of treatment ... [where] 6.26 mg carvedilol per single unit for a period of 7-28 days, [is] given one or twice daily.")
22	*See* exemplary support for claim 1, above.
23	*See* exemplary support for claim 12, above.
24	*See* exemplary support for claim 13, above.
25	*See, e.g.*, col. 4, ln. 5-31; claim 8.
26	*See, e.g.,* col. 5, ln. 19 – col. 6, ln. 15; claim 10; *see also* exemplary support for claim 1, above.
27	*See* exemplary support for claim 1, above.
28	*See* exemplary support for claim 12, above.
29	*See* exemplary support for claim 13, above.
30	*See, e.g.,* col. 5, ln. 19 – col. 6, ln. 15; claim 11.

For the benefit of the Examiner, Applicants provide the following additional explanation related to the new independent claims presented in this Preliminary Amendment.

Claim 20 is based on issued claim 7, but narrows the claimed subject matter. Specifically, in contrast to claim 7, which recites, *inter alia*, "said first dosages each comprising carvedilol in an amount of about 3.125 mg or 6.25 mg," claim 13 recites, *inter alia*, --said first dosages each comprising carvedilol in an amount of about 3.125 mg--. Claim 13 is, thus, more narrow than claim 7 because the first daily dosage is limited to --about 3.125 mg-- as compared with the broader limitation of "about 3.125 mg or 6.25 mg."

Claim 26 is based on issued claim 10, but narrows the claimed subject matter. Specifically, claim 26 recites the additional limitations "administering to said patient third dosages daily for a maintenance period to decrease a risk of mortality caused by

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

congestive heart failure, said third dosages each comprising carvedilol, said maintenance period is greater than six months," where the additions are shown as underlined text.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: November 25, 2003

By: _____
Mark J. Feldstein
Reg. No. 46,693

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com